Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Here's How Much You Would Have Made Owning Incyte Stock In The Last 20 Years
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $25.75 billion.read more...
Benzinga
More News
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte Corporation (Nasdaq: INCY) announced today that it granted restricted stock unit awards (RSUs) representing an aggregate of 21,556 shares of the Companys common stock and stock option awards to purchase an aggregate of 18,172 shares of the Companys common stock to 24 new employees. The...
Business Wire
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
Zacks
REGN or INCY: Which Is the Better Value Stock Right Now?
REGN vs. INCY: Which Stock Is the Better Value Option?
Zacks
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS PR Newswire SINGAPORE, Aug. 2, 2026 Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, is the first...
PR Newswire
Here's Why Incyte (INCY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod
The European Commission on Wednesday approved Incyte’s Opzelura cream as the first steroid-free topical treatment of its kind for adults with moderate eczema who do not get enough relief from standard creams.
Stocktwits
Here's Why Incyte (INCY) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Opzelura (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Opzelura (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate...
Business Wire
Incyte Says It's No Longer A One-Drug Story
Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance raised. Shares rally to new 52-week high.read more...
Benzinga

Advertisement|Remove ads.